the aid library

LIST OPTIONS

Filter

10080

Actualización epidemiológica - Cólera - 25 de octubre de 2022

Pan American Health Organization (PAHO) (2022) C_WHO

Desde la notificación de los dos primeros casos confirmados de Vibrio cholerae O1 en el área del gran Puerto Príncipe el 2 de octubre de 2022, al 23 de octubre de 2022, el Ministerio de Salud de Haití (Ministère de la Santé Publique et de la Population, MSPP por sus siglas en francés), inform... more

Download (1418)

View PDF (7973)

How to Hand wash
recommended

World Health Organization WHO (2009) C_WHO

Poster

Download (716)

View PDF (912)

Evidence of the risks and benefits of vaccinating pregnant women with WHO pre-qualified cholera vaccines during mass campaigns

Global Task Force on Cholera Control (GTFCC) World Health Organisation (WHO) (2016) C_WHO

The technical note from the Global Task Force on Cholera Control (GTFCC) examines the risks and benefits of vaccinating pregnant women with WHO-prequalified oral cholera vaccines (OCVs) during mass vaccination campaigns. It highlights that three WHO-approved vaccines (Dukoral®, Shanchol™, and Euv... more

Download (355)

View PDF (429)

Prise en charge clinique de la diarrhée aigue

Organisation Mondiale de la Santé OMS (2004) C_WHO

Le document fournit des lignes directrices sur la gestion des diarrhées aiguës, mettant en avant des solutions de réhydratation orale (SRO) améliorées avec une osmolarité réduite et la supplémentation en zinc. Il souligne leur efficacité pour réduire la durée et la gravité des épisodes ... more

Download (137)

View PDF (134)

Traitement d’urgence du paludisme sévère chez l’enfant par application intranasale d’artésunate

Yobouet I.K. Université Claude Bernard Lyon (2022) C2

La thèse de Yobouet Inès Kouakou, soutenue à l’Université Claude Bernard Lyon 1, porte sur le traitement d’urgence du paludisme sévère chez l’enfant à l’aide d’une administration intranasale d’artésunate. L’objectif principal de ce travail est d’explorer, in vitro, la voie na... more

Download (74)

View PDF (62)

Déploiement du traitement préventif intermittent du paludisme pendant la grossesse à base de sulfadoxine-pyriméthamine dans les communautés: guide du terrain

Organisation Mondiale de la Santé OMS (2024) C_WHO

Le guide décrit les étapes essentielles et donne des orientations aux pays pour l’adoption et le déploiement du c-TPIg de manière à l’intégrer dans le système de santé existant. Il s’appuie sur les meilleures pratiques et les enseignements tirés des expériences pilotes dans 8 pays af... more

Download (36)

View PDF (37)

Malaria in Children

Temu A., Kabyemela G. (2025) C2

Malaria in children presents significant clinical challenges, with variations in presentation based on the malaria parasite involved and the child's underlying health conditions. The World Health Organization reports high incidence rates, particularly in sub-Saharan Africa, and emphasizes the import... more

Download (43)

View PDF (29)

Management of Malaria in Pregnancy

Ministry of Health of Uganda (2025) C1

Accessed June 2025. This document outlines the Ministry of Health's management guidelines for malaria in pregnancy in Uganda. Pregnant women without malaria symptoms receive intermittent preventive treatment in pregnancy (IPTp) using sulfadoxine-pyrimethamine (SP) as directly observed therapy (DOT),... more

Download (786)

View PDF (1515)

Gestion des dépouilles mortelles lors de catastrophes : manuel pratique à l’usage des premiers intervenants. 2ième éd., rév.

Cordner, S.; Coninx, R.; Kim, J.-J. et al. (Éd.) Organisation mondiale de la santé (OMS), Organisation panaméricaine de la santé, Fédération internationale des Sociétés de la Croix-Rouge et du Croissant-Rouge (2016) C_WHO

La deuxième édition de ce manuel fournit des directives simples, concrètes et faciles à suivre pour la récupération et le stockage des corps des personnes décédées lors de catastrophes et l’enregistrement des informations les concernant, l’objectif étant d’aider les premiers interven... more

Download (1266)

View PDF (2497)

Health Preparedness For El Niño Event 2015-2016

World Health Organization (WHO) (2015) C_WHO

The WHO report on health preparedness for El Niño 2015-2016 describes the impact of this weather phenomenon on global public health. Strong El Niño events lead to extreme weather conditions, including droughts, floods, and storms, which increase the risk of diseases such as cholera, malaria, and d... more

Download (177)

View PDF (425)

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease

Institute for Health Metrics and Evaluation - University of Washington The Lancet (2017) CC2

The Global Status Report on Noncommunicable Diseases (NCDs) 2014 by the World Health Organization outlines the global impact of NCDs, including cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases, which are responsible for a significant portion of global mortality, particular... more

Download (262)

View PDF (633)

La Situation des enfants dans le monde 2023

UN Children's Fund UNICEF (2024) CC

The article focuses on "The State of the World’s Children 2023" report published by UNICEF. It highlights the critical role of vaccines in saving lives and the challenges in global immunization efforts, especially for marginalized and underserved children. The report emphasizes the impact of COVID... more

Download (1933)

View PDF (3260)

Cómo combatir el cólera: Presentación y manejo clínico para el brote de cólera en Haití de 2010

CDC, U.S. Department of Health and Human Services (2010) C_CDC

The document titled "Cómo combatir el cólera" (How to Combat Cholera) provides comprehensive guidelines on the clinical presentation and management of cholera, particularly in the context of the 2010 Haiti outbreak. It emphasizes the importance of rapid rehydration as a lifesaving measure, deta... more

Download (246)

View PDF (631)

Estado Mundial de la Infancia 2023

UN Children's Fund UNICEF (2024) CC

Download (473)

View PDF (698)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more